Geron granted Oncolys exclusive, worldwide rights to develop and commercialize in vitro diagnostic assays using human telomerase specific reverse transcriptase (hTERT) promoter patents

Geron Corp.

U.S. / Small-Cap Biopharma (<$1 billion)

$147.5m on 03/15/2013 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Oncolys BioPharma Inc.

Japan / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced